Physician profile
Sarah E Chen
NPI 1841642634
$1,507.13
in general payments reported to CMS, 2019-2025
22 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.54 · 2022: $235 · 2023: $426 · 2024: $427 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.09 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.38 | 2023-2025 | |
| Novo Nordisk INC | $237.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $214.89 | 2023-2025 | |
| Lilly USA, LLC | $131.31 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boston Scientific Corporation | $75.69 | 2024-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $71.95 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $66.34 | 2022-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $56.36 | 2023 | Veozah, Myrbetriq |
| Scpharmaceuticals INC. | $56.09 | 2024-2025 | |
| Amgen INC. | $46.95 | 2022-2023 | Otezla, Repatha |
| Currax Pharmaceuticals LLC | $40.15 | 2023 | Nexletol, Contrave |
| Idorsia Pharmaceuticals US INC | $38.43 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.97 | 2024-2025 | Xifaxan |
| Eisai INC. | $28.79 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.51 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $23.60 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.69 | 2023 | Xarelto |
| Sanofi Pasteur INC. | $19.30 | 2022 | |
| Mylan Specialty L.P. | $18.13 | 2024 | Yupelri |
| Almatica Pharma LLC | $15.95 | 2022 | |
| Merck Sharp & Dohme LLC | $14.97 | 2021 | |
| Stryker Corporation | $12.72 | 2023 | Infinity Adaptis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.